Grant: Project Grant
University of Calgary
$100,000.00
TEMPO-2 - Multicentre, prospective randomized open label, blinded-endpoint (PROBE) controlled trial of thrombolysis with low dose Tenecteplase (TNK-tPA) versus standard of care in the prevention of disability at 3 months in minor ischemic stroke with proven acute symptomatic occlusion.
EF 2016-17
Résumé
Most minor strokes are due to lack of blood getting to a part of the brain. When this occurs, patients get sudden loss of function in that region of the brain. This might mean inability to move a limb or inability to speak. In the luckiest case, this dysfunction resolves rapidly by itself and we call it a transient ischemic attach (TIA). If less lucky, the disability persists due a minor stroke. Minor stroke and TIA account for about 50% of all strokes in Canada.
Most physicians think that patients with minor stroke or TIA do not need aggressive treatment with clot busting drugs because the risk of bleeding in the brain is greater than any benefit. However, we believe that this judgment is incorrect. We have shown that minor stroke and TIA patients with evidence of a blocked blood vessel on a brain scan are at a very high risk of being left disabled with conservative treatment. This subgroup of patients can benefit from aggressive therapy with clot-busting drugs.
The usual clot-busting drug usually used in Stroke is called tPA. A newer drug used in patients with heart attack called TNK works faster and is safer than tPA. In the TEMPO-2 clinical trial, we will determine if TNK, given as a single dose, is better than usual care for patients with minor stroke with a proven blocked artery. Patients will have a 50:50 chance (i.e. like the toss of a coin) of getting either treatment or usual care. Patients will be assessed 3 months after the event for evidence of disability. If this study shows that the clot besting medicine should be used in minor stroke and TIA with blocked blood vessels then this will change care of patients throughout the world.
Programme
Project Grant
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
351760
Name
Coutts Shelagh B
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Project Grant Competition
Projecttitle
TEMPO-2 - Multicentre, prospective randomized open label, blinded-endpoint (PROBE) controlled trial of thrombolysis with low dose Tenecteplase (TNK-tPA) versus standard of care in the prevention of disability at 3 months in minor ischemic stroke with proven acute symptomatic occlusion.
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Disability; Randomized Clinical Trial; Stroke; Thrombolysis
Abstract
Most minor strokes are due to lack of blood getting to a part of the brain. When this occurs, patients get sudden loss of function in that region of the brain. This might mean inability to move a limb or inability to speak. In the luckiest case, this dysfunction resolves rapidly by itself and we call it a transient ischemic attach (TIA). If less lucky, the disability persists due a minor stroke. Minor stroke and TIA account for about 50% of all strokes in Canada.
Most physicians think that patients with minor stroke or TIA do not need aggressive treatment with clot busting drugs because the risk of bleeding in the brain is greater than any benefit. However, we believe that this judgment is incorrect. We have shown that minor stroke and TIA patients with evidence of a blocked blood vessel on a brain scan are at a very high risk of being left disabled with conservative treatment. This subgroup of patients can benefit from aggressive therapy with clot-busting drugs.
The usual clot-busting drug usually used in Stroke is called tPA. A newer drug used in patients with heart attack called TNK works faster and is safer than tPA. In the TEMPO-2 clinical trial, we will determine if TNK, given as a single dose, is better than usual care for patients with minor stroke with a proven blocked artery. Patients will have a 50:50 chance (i.e. like the toss of a coin) of getting either treatment or usual care. Patients will be assessed 3 months after the event for evidence of disability. If this study shows that the clot besting medicine should be used in minor stroke and TIA with blocked blood vessels then this will change care of patients throughout the world.
Competitiondate
201604
Approvedterm2
1 yr 0 mth
Pinamesdelim
Coutts, Shelagh B; Goyal, Mayank; Hill, Michael D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~